2,484 results on '"Barnett M."'
Search Results
2. P.011 Efficacy and safety of ravulizumab in adults with AQP4+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial
- Author
-
Pittock, SJ, primary, Barnett, M, additional, Bennett, JL, additional, Berthele, A, additional, de Sèze, J, additional, Levy, M, additional, Nakashima, I, additional, Oreja-Guevara, C, additional, Palace, J, additional, Paul, F, additional, Pozzilli, C, additional, Mashhoon, Y, additional, Allen, K, additional, Parks, B, additional, Kim, H, additional, and Vorobeychik, G, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Jupiter's Mesoscale Waves Observed at 5 $\mu$m by Ground-Based Observations and Juno JIRAM
- Author
-
Fletcher, L. N., Melin, H., Adriani, A., Simon, A. A., Sanchez-Lavega, A., Donnelly, P. T., Antunano, A., Orton, G. S., Hueso, R., Kraaikamp, E., Wong, M. H., Barnett, M., Moriconi, M. L., Altieri, F., and Sindoni, G.
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We characterise the origin and evolution of a mesoscale wave pattern in Jupiter's North Equatorial Belt (NEB), detected for the first time at 5 $\mu$m using a 2016-17 campaign of `lucky imaging' from the VISIR instrument on the Very Large Telescope and the NIRI instrument on the Gemini observatory, coupled with M-band imaging from Juno's JIRAM instrument during the first seven Juno orbits. The wave is compact, with a $1.1-1.4^\circ$ longitude wavelength (wavelength 1,300-1,600 km, wavenumber 260-330) that is stable over time, with wave crests aligned largely north-south between $14$ and $17^\circ$N (planetographic). The waves were initially identified in small ($10^\circ$ longitude) packets immediately west of cyclones in the NEB at $16^\circ$N, but extended to span wider longitude ranges over time. The waves exhibit a 7-10 K brightness temperature amplitude on top of a $\sim210$-K background at 5 $\mu$m. The thermal structure of the NEB allows for both inertio-gravity waves and gravity waves. Despite detection at 5 $\mu$m, this does not necessarily imply a deep location for the waves, and an upper tropospheric aerosol layer near 400-800 mbar could feature a gravity wave pattern modulating the visible-light reflectivity and attenuating the 5-$\mu$m radiance originating from deeper levels. Strong rifting activity appears to obliterate the pattern, which can change on timescales of weeks. The NEB underwent a new expansion and contraction episode in 2016-17 with associated cyclone-anticyclone formation, which could explain why the mesoscale wave pattern was more vivid in 2017 than ever before., Comment: 17 pages, 9 figures, published in Astronomical Journal
- Published
- 2018
- Full Text
- View/download PDF
4. The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research.
- Author
-
Ofili, Elizabeth O, Tchounwou, Paul B, Fernandez-Repollet, Emma, Yanagihara, Richard, Akintobi, Tabia H, Lee, Jae E, Malouhi, Mohamad, Garner, Solomon T, Hayes, Traci T, Baker, Almelida R, Dent, Andrew L, Abdelrahim, Muna, Rollins, Latrice, Chang, Sandra P, Sy, Angela, Hernandez, Brenda Y, Bullard, Pamela L, Noel, Richard J, Shiramizu, Bruce, Hedges, Jerris R, Berry, Marla J, Bond, Vincent C, Lima, Maria F, Mokuau, Noreen, Kirken, Robert A, Cruz-Correa, Marcia, Sarpong, Daniel F, Vadgama, Jaydutt, Yates, Clayton, Kahn, Shafiq A, Soliman, Karam F, Perry, George, Pezzano, Mark, Luciano, Carlos A, Barnett, M Edwina, Oyekan, Adebayo, Kumar, Deepak, and Norris, Keith C
- Subjects
Health Services and Systems ,Health Sciences ,Behavioral and Social Science ,Clinical Research ,American Indian or Alaska Native ,Basic Behavioral and Social Science ,Generic health relevance ,Good Health and Well Being ,Behavioral Research ,Biomedical Research ,Cultural Diversity ,Ethnicity ,Health Status Disparities ,Humans ,Minority Groups ,Minority Health ,Research Personnel ,Research Support as Topic ,Translational Research ,Biomedical ,United States ,Workforce ,Minority-serving Institutions ,Underrepresented ,Health Inequities ,Workforce Diversity ,RCMI Investigators and RTRN Team Members ,Public Health and Health Services ,Public Health ,Epidemiology ,Public health - Abstract
The Research Centers in Minority Institutions (RCMI) program was established by the US Congress to support the development of biomedical research infrastructure at minority-serving institutions granting doctoral degrees in the health professions or in a health-related science. RCMI institutions also conduct research on diseases that disproportionately affect racial and ethnic minorities (ie, African Americans/Blacks, American Indians and Alaska Natives, Hispanics, Native Hawaiians and Other Pacific Islanders), those of low socioeconomic status, and rural persons. Quantitative metrics, including the numbers of doctoral science degrees granted to underrepresented students, NIH peer-reviewed research funding, peer-reviewed publications, and numbers of racial and ethnic minorities participating in sponsored research, demonstrate that RCMI grantee institutions have made substantial progress toward the intent of the Congressional legislation, as well as the NIH/NIMHD-linked goals of addressing workforce diversity and health disparities. Despite this progress, nationally, many challenges remain, including persistent disparities in research and career development awards to minority investigators. The continuing underrepresentation of minority investigators in NIH-sponsored research across multiple disease areas is of concern, in the face of unrelenting national health inequities. With the collaborative network support by the RCMI Translational Research Network (RTRN), the RCMI community is uniquely positioned to address these challenges through its community engagement and strategic partnerships with non-RCMI institutions. Funding agencies can play an important role by incentivizing such collaborations, and incorporating metrics for research funding that address underrepresented populations, workforce diversity and health equity.
- Published
- 2019
5. The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease
- Author
-
Norris, Keith C, Olabisi, Opeyemi, Barnett, M Edwina, Meng, Yuan-Xiang, Martins, David, Obialo, Chamberlain, Lee, Jae Eun, and Nicholas, Susanne B
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Kidney Disease ,Renal and urogenital ,Good Health and Well Being ,Ethnicity ,Health Surveys ,Humans ,Male ,Middle Aged ,Oxidative Stress ,Prevalence ,Renal Insufficiency ,Chronic ,United States ,Vitamin D ,Vitamin D Deficiency ,vitamin D ,oxidative stress ,kidney disease ,disparities ,Toxicology - Abstract
Chronic kidney disease (CKD) is a major non-communicable disease associated with high rates of premature morbidity and mortality. The prevalence of hypovitaminosis D (deficiency of 25(OH)D or 25D) is greater in racial/ethnic minorities and in patients with CKD than the general population. Low 25D is associated with bone and mineral disorders as well as immune, cardiometabolic and cardiovascular (CV) diseases. Thus, it has been suggested that low 25D contributes to the poor outcomes in patients with CKD. The prevalence of hypovitaminosis D rises progressively with advancing severity of kidney disease with over 30% of patients with CKD stage 3 and 70% patients with CKD stage 5 estimated to have low levels of 25D. This report describes several of the abnormal physiologic and counter-regulatory actions related to low 25D in CKD such as those in oxidative stress and inflammatory systems, and some of the preclinical and clinical evidence, or lack thereof, of normalizing serum 25D levels to improve outcomes in patients with CKD, and especially for the high risk subset of racial/ethnic minorities who suffer from higher rates of advanced CKD and hypovitaminosis D.
- Published
- 2018
6. How Can We Best Measure the Performance of Scleral Lenses? Current Insights
- Author
-
Macedo-de-Araújo RJ, Fadel D, and Barnett M
- Subjects
scleral lens ,performance ,instrumentation ,Ophthalmology ,RE1-994 - Abstract
Rute J Macedo-de-Araújo,1 Daddi Fadel,2 Melissa Barnett3 1Clinical & Experimental Optometry Research Laboratory (CEORLab), Physics Centre of Minho and Porto Universities (CF-UM-UP), University of Minho, Braga, Portugal; 2Private Practice, Rieti, Italy; 3Davis Eye Center, University of California, Sacramento, CA, USACorrespondence: Rute J Macedo-de-Araújo, Email rjfmaraujo@gmail.comAbstract: Scleral lenses (SLs) present several unique advantageous characteristics for patients. As these lenses are mainly fitted in severely diseased eyes, a thorough evaluation of the ocular surface before and after SL fitting and the on-eye SL fitting evaluation are essential and help minimize potential physiological complications. This review will explore the current and emerging techniques and instrumentation to best measure SL performance ensuring optimal lens fitting, visual quality, comfort and physiological responses, highlighting some potential complications and follow-up recommendations. A single physician could perform the great majority of evaluations. Still, the authors consider that the assessment of SL fitting should be a collaborative and multidisciplinary job, involving contact lens practitioners, ophthalmologists and the industry. This publication has reviewed the most up-to-date work and listed the most used techniques; however, the authors encourage the development of more evidence-based recommendations for SL clinical practice.Keywords: scleral lens, performance, instrumentation
- Published
- 2022
7. UN-UB[formula omitted] Composite fuel material; improved water tolerance with integral burnable absorber
- Author
-
Turner, J., Buckley, J., Worth, R.N., Salata-Barnett, M., Schmidt, M.J.J., and Abram, T.J.
- Published
- 2022
- Full Text
- View/download PDF
8. Rationale and design of a placebo controlled randomized trial to assess short term, high-dose oral cholecalciferol on select laboratory and genomic responses in African Americans with hypovitaminosis D
- Author
-
Norris, Keith C, Barnett, M Edwina, Meng, Yuan-Xiang, Martins, David, Nicholas, Susanne B, Gibbons, Gary H, and Lee, Jae Eun
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Genetics ,Clinical Research ,Nutrition ,Cardiovascular ,Heart Disease ,Clinical Trials and Supportive Activities ,Obesity ,Prevention ,Diabetes ,6.1 Pharmaceuticals ,Metabolic and endocrine ,Good Health and Well Being ,Black or African American ,Cholecalciferol ,Cytokines ,Double-Blind Method ,Humans ,Hypertension ,Inflammation ,Insulin Resistance ,Overweight ,Parathyroid Hormone ,Vitamin D Deficiency ,Vitamin D-Binding Protein ,Vitamins ,Randomized Controlled Trials as Topic ,Vitamin D ,Randomized controlled trial ,Nutrigenomics ,Race ,Disparities ,African American ,Cardiovascular disease ,Medical and Health Sciences ,General Clinical Medicine ,Public Health ,Biomedical and clinical sciences ,Health sciences - Abstract
Cardiovascular Disease (CVD) and related disorders remain a leading cause of health disparities and premature death for African Americans. Hypovitaminosis D is disproportionately prevalent in African Americans and has been linked to CVD and CVD risk factors including hypertension, diabetes and obesity. Thus, hypovitaminosis D may represent a common pathway influencing CV risk factors in a select subgroup of persons. The purpose of this paper is to report the study design of a prospective eight week prospective double-blind randomized, placebo-controlled trial (n = 330 allocated 2:1 to intervention vs. control) to assess the effect of placebo vs. high-dose oral cholecalciferol (100,000 IU vitamin D3 at baseline and week 2) on 6-week change of select biologic cardiometabolic risk factors (including parathyroid hormone to assess biologic activity, pro-inflammatory/pro-thrombotic/fibrotic markers, insulin sensitivity and vitamin D metabolites) and their relationship to vitamin D administration and modification by vitamin D receptor polymorphisms in overweight, hypertensive African Americans with hypovitaminosis D. Findings from this trial will present insights into potential causal links between vitamin D repletion and mechanistic pathways of CV disease, including established and novel genomic markers.
- Published
- 2018
9. Presbyopia Treatments by Mechanism of Action: A New Classification System Based on a Review of the Literature
- Author
-
Chang DH, Waring GO 4th, Hom M, and Barnett M
- Subjects
accommodation ,presbyopia ,functional through focus ,Ophthalmology ,RE1-994 - Abstract
Daniel H Chang,1 George O Waring 4th,2 Milton Hom,3 Melissa Barnett4 1Empire Eye and Laser Center, Bakersfield, CA, USA; 2Waring Vision Institute, Mt. Pleasant, SC, USA; 3Canyon City Eyecare, Azusa, CA, USA; 4University of California, Davis Eye Center, Sacramento, CA, USACorrespondence: Daniel H ChangEmpire Eye and Laser Center, 4105 Empire Drive, Bakersfield, CA, 93309, USAEmail dchang@empireeyeandlaser.comAbstract: Presbyopia, a loss of accommodative ability associated with aging, is a significant cause of vision impairment globally. At the clinical level, it is a frustrating and difficult issue that negatively impacts patients’ quality of life. Less appreciated is the fact that loss of accommodative ability and its current treatments methods may present safety concerns, for example, increasing the risk of falls. Therefore, a more complete understanding of treatment options with respect to how they relate to the natural ability of the eye is needed to improve decision making and to aid clinicians in individualizing treatment options. This article reviews the options for expanding functional through focus—a term coined to describe the ability of the eye to see at all distances with minimal latency—by how they vary the refractive power over time, across the visual field, between eyes, or across a range of distances.Keywords: accommodation, presbyopia, functional through focus
- Published
- 2021
10. TEM Study of Facet Junctions in YBa2Cu3O7-δ/PrBa2Cu3O7-δ Thin Film Patterned Multilayer Structures
- Author
-
Barnett, M, primary, Aindow, M, additional, Abell, JS, additional, Hirst, PJ, additional, Chew, NG, additional, and Humphreys, RG, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Unchaining Supply Chains: Transformative Leaps Toward Regenerating Social-Ecological Systems
- Author
-
Gualandris, J, Branzei, O, Wilhelm, M, Lazzarini, S, Linnenluecke, M, Hamann, R, Dooley, K, Barnett, M, Chen, C-M, Gualandris, J, Branzei, O, Wilhelm, M, Lazzarini, S, Linnenluecke, M, Hamann, R, Dooley, K, Barnett, M, and Chen, C-M
- Published
- 2024
12. Therapist Reports of EBP Client Engagement Challenges in Sessions with Diverse Youth and Families in Community Mental Health Settings
- Author
-
Gellatly, R., Brookman-Frazee, L., Barnett, M., Gonzalez, J. C., Kim, J. J., and Lau, A. S.
- Abstract
Background: The implementation of evidence-based practices (EBPs) in community settings appears to result in reduced benefit relative to controlled trials. This difference in outcomes may be attributable in part to engagement challenges therapists encounter when delivering EBPs to low-income ethnic minority youth and families. Objective: The current study sought to identify therapist, client, and session characteristics associated with therapist-reported engagement challenges in therapy sessions, as well the associations between two types of client engagement challenges and therapists' self-reported ability to deliver the EBP in sessions within a system-driven implementation in public children's mental health services. Method: One hundred and three therapists reported on two types of engagement challenges--Limited Client Engagement and Expressed Client Concerns--in 702 sessions with 274 clients. Results: Results indicated that therapists reported a higher frequency of Limited Client Engagement in sessions with male clients and in sessions where the youth was present, and by therapists with smaller caseloads. No variables significantly predicted Expressed Client Concerns. Both types of engagement challenges were negatively associated with therapists' report of their ability to carry out intended activities in the same session. Conclusions: Findings suggest that therapists may benefit from learning strategies to address these two distinct types of engagement challenges encountered in implementation of EBPs with diverse families in community settings.
- Published
- 2019
- Full Text
- View/download PDF
13. Diffusion magnetic resonance imaging assessment of regional white matter maturation in preterm neonates
- Author
-
Kimpton, J. A., Batalle, D., Barnett, M. L., Hughes, E. J., Chew, A. T. M., Falconer, S., Tournier, J. D., Alexander, D., Zhang, H., Edwards, A. D., and Counsell, S. J.
- Published
- 2021
- Full Text
- View/download PDF
14. P1012 Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program
- Author
-
Barnett, M, primary, Mcnamara, J, additional, Wilson, W, additional, Pipicella, J, additional, Ghaly, S, additional, Gearry, R, additional, Begun, J, additional, Williams, A, additional, Lynch, K, additional, Lawrance, I, additional, Schultz, M, additional, Walker, G, additional, Radford-Smith, G, additional, Connor, S J, additional, and Andrews, J M, additional
- Published
- 2024
- Full Text
- View/download PDF
15. User-Friendly Data-Sharing Practices for Fostering Collaboration within a Research Network: Roles of a Vanguard Center for a Community-Based Study
- Author
-
Lee, Jae Eun, Sung, Jung Hye, Barnett, M Edwina, and Norris, Keith
- Subjects
Information and Computing Sciences ,Library and Information Studies ,Clinical Research ,Good Health and Well Being ,Adult ,Black or African American ,Aged ,Aged ,80 and over ,Cardiovascular Diseases ,Cooperative Behavior ,Female ,Humans ,Information Dissemination ,Longitudinal Studies ,Male ,Middle Aged ,Minority Groups ,Prospective Studies ,Research Design ,United States ,data-sharing practice ,research network ,role of coordinating center ,Toxicology - Abstract
Although various attempts have been made to build collaborative cultures for data sharing, their effectiveness is still questionable. The Jackson Heart Study (JHS) Vanguard Center (JHSVC) at the NIH-funded Research Centers in Minority Institutions (RCMI) Translational Research Network (RTRN) Data Coordinating Center (DCC) may be a new concept in that the data are being shared with a research network where a plethora of scientists/researchers are working together to achieve their common goal. This study describes the current practices to share the JHS data through the mechanism of JHSVC. The JHS is the largest single-site cohort study to prospectively investigate the determinants of cardiovascular disease among African-Americans. It has adopted a formal screened access method through a formalized JHSVC mechanism, in which only a qualified scientist(s) can access the data. The role of the DCC was to help RTRN researchers explore hypothesis-driven ideas to enhance the output and impact of JHS data through customized services, such as feasibility tests, data querying, manuscript proposal development and data analyses for publication. DCC has implemented these various programs to facilitate data utility. A total of 300 investigators attended workshops and/or received training booklets. DCC provided two online and five onsite workshops and developed/distributed more than 250 copies of the booklet to help potential data users understand the structure of and access to the data. Information on data use was also provided through the RTRN website. The DCC efforts led to the production of five active manuscript proposals, seven completed publications, 11 presentations and four NIH grant proposals. These outcomes resulted from activities during the first four years; over the last couple of years, there were few new requests. Our study suggested that DCC-customized services enhanced the accessibility of JHS data and their utility by RTRN researchers and helped to achieve the principal goal of JHSVC of scientific productivity. In order to achieve long-term success, the following, but not limited to these, should be addressed in the current data sharing practices: preparation of new promotional strategies in response to changes in technology and users' needs, collaboration with the Network statisticians, harmonization of the JHS data with the other local-based heart datasets to meet the needs of the potential users from the broader geographical areas, adoption of the RTRN comprehensive data-sharing policy to broaden the variety of research topics and implementation of an ongoing monitoring program to evaluate its success.
- Published
- 2016
16. TFOS Lifestyle: Impact of contact lenses on the ocular surface
- Author
-
Jones, L, Efron, N, Bandamwar, K, Barnett, M, Jacobs, D, Jalbert, I, Pult, H, Rhee, M, Sheardown, H, Shovlin, J, Stahl, U, Stanila, A, Tan, J, Tavazzi, S, Ucakhan, O, Willcox, M, Downie, L, Jones L., Efron N., Bandamwar K., Barnett M., Jacobs D. S., Jalbert I., Pult H., Rhee M. K., Sheardown H., Shovlin J. P., Stahl U., Stanila A., Tan J., Tavazzi S., Ucakhan O. O., Willcox M. D. P., Downie L. E., Jones, L, Efron, N, Bandamwar, K, Barnett, M, Jacobs, D, Jalbert, I, Pult, H, Rhee, M, Sheardown, H, Shovlin, J, Stahl, U, Stanila, A, Tan, J, Tavazzi, S, Ucakhan, O, Willcox, M, Downie, L, Jones L., Efron N., Bandamwar K., Barnett M., Jacobs D. S., Jalbert I., Pult H., Rhee M. K., Sheardown H., Shovlin J. P., Stahl U., Stanila A., Tan J., Tavazzi S., Ucakhan O. O., Willcox M. D. P., and Downie L. E.
- Abstract
Several lifestyle choices made by contact lens wearers can have adverse consequences on ocular health. These include being non-adherent to contact lens care, sleeping in lenses, ill-advised purchasing options, not seeing an eyecare professional for regular aftercare visits, wearing lenses when feeling unwell, wearing lenses too soon after various forms of ophthalmic surgery, and wearing lenses when engaged in risky behaviors (e.g., when using tobacco, alcohol or recreational drugs). Those with a pre-existing compromised ocular surface may find that contact lens wear exacerbates ocular disease morbidity. Conversely, contact lenses may have various therapeutic benefits. The coronavirus disease-2019 (COVID-19) pandemic impinged upon the lifestyle of contact lens wearers, introducing challenges such as mask-associated dry eye, contact lens discomfort with increased use of digital devices, inadvertent exposure to hand sanitizers, and reduced use of lenses. Wearing contact lenses in challenging environments, such as in the presence of dust and noxious chemicals, or where there is the possibility of ocular trauma (e.g., sport or working with tools) can be problematic, although in some instances lenses can be protective. Contact lenses can be worn for sport, theatre, at high altitude, driving at night, in the military and in space, and special considerations are required when prescribing in such situations to ensure successful outcomes. A systematic review and meta-analysis, incorporated within the review, identified that the influence of lifestyle factors on soft contact lens dropout remains poorly understood, and is an area in need of further research. Overall, this report investigated lifestyle-related choices made by clinicians and contact lens wearers and discovered that when appropriate lifestyle choices are made, contact lens wear can enhance the quality of life of wearers.
- Published
- 2023
17. Optical and Microstructural Origins of Thermomechanical Streaking Defects in Hot Extruded AA6060
- Author
-
Babaniaris, S., Beer, A. G., and Barnett, M. R.
- Published
- 2019
- Full Text
- View/download PDF
18. Direct phase determination in protein crystallography using iterative projection algorithms
- Author
-
Kingston, R. L., primary, Barnett, M. J., additional, and Millane, R. P., additional
- Published
- 2023
- Full Text
- View/download PDF
19. Development in a novel approach to visualising large amounts of dynamic protein data in real time, using Unreal Engine 5
- Author
-
Barnett, M. J., primary
- Published
- 2023
- Full Text
- View/download PDF
20. Supersymmetry Parameter Analysis: SPA Convention and Project
- Author
-
Aguilar-Saavedra, J. A., Ali, A., Allanach, B. C., Arnowitt, R., Baer, H. A., Bagger, J. A., Balazs, C., Barger, V., Barnett, M., Bartl, A., Battaglia, M., Bechtle, P., Belanger, G., Belyaev, A., Berger, E. L., Blair, G., Boos, E., Carena, M., Choi, S. Y., Deppisch, F., De Roeck, A., Desch, K., Diaz, M. A., Djouadi, A., Dutta, B., Dutta, S., Eberl, H., Ellis, J., Erler, J., Fraas, H., Freitas, A., Fritzsche, T., Godbole, R. M., Gounaris, G. J., Guasch, J., Gunion, J., Haba, N., Haber, H. E., Hagiwara, K., Han, L., Han, T., He, H. -J., Heinemeyer, S., Hesselbach, S., Hidaka, K., Hinchliffe, I., Hirsch, M., Hohenwarter-Sodek, K., Hollik, W., Hou, W. S., Hurth, T., Jack, I., Jiang, Y., Jones, D. R. T., Kalinowski, J., Kamon, T., Kane, G., Kang, S. K., Kernreiter, T., Kilian, W., Kim, C. S., King, S. F., Kittel, O., Klasen, M., Kneur, J. -L., Kovarik, K., Kramer, M., Kraml, S., Lafaye, R., Langacker, P., Logan, H. E., Ma, W. -G., Majerotto, W., Martyn, H. -U., Matchev, K., Miller, D. J., Mondragon, M., Moortgat-Pick, G., Moretti, S., Mori, T., Moultaka, G., Muanza, S., Muhlleitner, M. M., Mukhopadhyaya, B., Nauenberg, U., Nojiri, M. M., Nomura, D., Nowak, H., Okada, N., Olive, K. A., Oller, W., Peskin, M., Plehn, T., Polesello, G., Porod, W., Quevedo, F., Rainwater, D., Reuter, J., Richardson, P., Rolbiecki, K., Roy, P., Ruckl, R., Rzehak, H., Schleper, P., Siyeon, K., Skands, P., Slavich, P., Stockinger, D., Sphicas, P., Spira, M., Tait, T., Tovey, D. R., Valle, J. W. F., Wagner, C. E. M., Weber, Ch., Weiglein, G., Wienemann, P., Xing, Z. -Z., Yamada, Y., Yang, J. M., Zerwas, D., Zerwas, P. M., Zhang, R. -Y., Zhang, X., and Zhu, S. -H.
- Subjects
High Energy Physics - Phenomenology - Abstract
High-precision analyses of supersymmetry parameters aim at reconstructing the fundamental supersymmetric theory and its breaking mechanism. A well defined theoretical framework is needed when higher-order corrections are included. We propose such a scheme, Supersymmetry Parameter Analysis SPA, based on a consistent set of conventions and input parameters. A repository for computer programs is provided which connect parameters in different schemes and relate the Lagrangian parameters to physical observables at LHC and high energy e+e- linear collider experiments, i.e., masses, mixings, decay widths and production cross sections for supersymmetric particles. In addition, programs for calculating high-precision low energy observables, the density of cold dark matter (CDM) in the universe as well as the cross sections for CDM search experiments are included. The SPA scheme still requires extended efforts on both the theoretical and experimental side before data can be evaluated in the future at the level of the desired precision. We take here an initial step of testing the SPA scheme by applying the techniques involved to a specific supersymmetry reference point., Comment: 17pp; references corrected
- Published
- 2005
- Full Text
- View/download PDF
21. Variation of the fine structure constant in QSO spectra from coherent dark matter oscillations
- Author
-
Barnett, M. G., Dick, R., and Wunderle, K. E.
- Subjects
Astrophysics - Abstract
We consider the problem of the evolution of the fine structure coefficient alpha under the assumption that the scalar field coupling to the Maxwell term satisfies the condition mt>>1 for coherent dark matter oscillations. In this case we find that the coupling scale f in the leading order coupling -(phi/4f)F^2 affects the cosmological evolution of alpha according to ln(alpha/alpha_0) xi(m_{Pl}/f)ln(tanh(t/2 tau)/tanh(t_0/2 tau)). A fit to the QSO observations by Murphy et al. yields f/xi= 2.12^{+0.58}_{-0.37} 10^5m_{Pl}. Here m_{Pl} is the reduced Planck mass, and xi^2=rho_phi/rho_m parametrizes the contribution of phi to the matter density in the universe., Comment: 6 pages, accepted for publication in the MNRAS
- Published
- 2004
- Full Text
- View/download PDF
22. Therapist Reports of EBP Client Engagement Challenges in Sessions with Diverse Youth and Families in Community Mental Health Settings
- Author
-
Gellatly, R., Brookman-Frazee, L., Barnett, M., Gonzalez, J. C., Kim, J. J., and Lau, A. S.
- Published
- 2019
- Full Text
- View/download PDF
23. Agreement and Reliability of Clinician-in-Clinic Versus Patient-at-Home Clinical and Functional Assessments: Implications for Telehealth Services
- Author
-
Shelley E. Keating, PhD, Amandine Barnett, M Nut & Diet Practice, Ilaria Croci, PhD, Amy Hannigan, BHSci (Nut & Diet), Louise Elvin-Walsh, BHSci (Nut & Diet), Jeff S. Coombes, PhD, Katrina L. Campbell, PhD, Graeme A. Macdonald, PhD, MBBS, and Ingrid J. Hickman, PhD
- Subjects
Chronic disease ,Rehabilitation ,Self-assessment ,Technology ,Telemedicine ,Medicine (General) ,R5-920 - Abstract
Objective: To compare agreement and reliability between clinician-measured and patient self-measured clinical and functional assessments for use in remote monitoring, in a home-based setting, using telehealth. Design: Reliability study: repeated-measure, within-subject design. Setting: Trained clinicians measured standard clinical and functional parameters at a face-to-face clinic appointment. Participants were instructed on how to perform the measures at home and to repeat self-assessments within 1 week. Participants: Liver transplant recipients (LTRs) (N=18) (52±14y, 56% men, 5.4±4.3y posttransplant] completed the home self-assessments. Interventions: Not applicable. Main Outcome Measures: The outcomes assessed were body weight, systolic and diastolic blood pressure (SBP and DBP), waist circumference, repeated chair sit-to-stand (STST), maximal push-ups, and the 6-minute walk test (6MWT). Intertester reliability and agreement between face-to-face clinician and self-reported home-based participant measures were determined by intraclass-correlation coefficients (ICCs) and Bland-Altman plots, which were compared with minimal clinically important differences (MCID) (determined a priori). Results: The mean difference (95% confidence interval) and [limits of agreement] for measures (where positive values indicate lower participant value) were weight, 0.7 (0.01-1.4) kg [−2.2 to 3.6kg]; waist 0.4 (−1.2 to 2.0) cm [−5.9 to 6.8cm]; SBP 7.7 (0.6-14.7 ) mmHg [−19.4 to 34.9mmHg]; DBP 2.4 (−1.4 to 6.2 ) mmHg [−12.2 to 17.0mmHg]; 6MWT, 7.5 (−29.1 to 44.1) m [−127.3 to 142.4m]; STST 0.5 (−0.8 to 1.7) seconds [−4.3 to 5.3s]; maximal push-ups −2.2 (−4.4 to −0.1) [−10.5 to 6.0]. ICCs were all >0.75 except for STST (ICC=0.73). Mean differences indicated good agreement than MCIDs; however, wide limits of agreement indicated large individual variability in agreement. Conclusions: Overall, LTRs can reliably self-assess clinical and functional measures at home. However, there was wide individual variability in accuracy and agreement, with no functional assessment being performed within acceptable limits relative to MCIDs >80% of the time.
- Published
- 2020
- Full Text
- View/download PDF
24. Short Communication: The effects of ageing and storage environment on the oxidation response of uranium nitride (UN) powders
- Author
-
Salata-Barnett, M., primary, Cartlidge, A., additional, Buckley, J., additional, Abram, T., additional, and Turner, J., additional
- Published
- 2023
- Full Text
- View/download PDF
25. On the Impact of Second Phase Particles on Twinning in Magnesium Alloys
- Author
-
Barnett, M. R., Stanford, N., Geng, J., Robson, J., Sillekens, Wim H., editor, Agnew, Sean R., editor, Neelameggham, Neale R., editor, and Mathaudhu, Suveen N., editor
- Published
- 2016
- Full Text
- View/download PDF
26. Effect of Zn Concentration and Grain Size on Prismatic Slip in Mg-Zn Binary Alloys
- Author
-
Stanford, N., Barnett, M. R., Mathaudhu, Suveen N., editor, Sillekens, Wim H., editor, Neelameggham, Neale R., editor, and Hort, Norbert, editor
- Published
- 2016
- Full Text
- View/download PDF
27. The Hot Working Flow Stress and Microstructure in Magnesium AZ31
- Author
-
Beer, A. G., Barnett, M. R., Mathaudhu, Suveen N., editor, Luo, Alan A., editor, Neelameggham, Neale R., editor, Nyberg, Eric A., editor, and Sillekens, Wim H., editor
- Published
- 2016
- Full Text
- View/download PDF
28. The collaboration readiness of transdisciplinary research teams and centers: Findings from the National Cancer Institute TREC Year-One Evaluation Study
- Author
-
Stokols, DS, Hall, KL, Moser, RP, Taylor, BK, Thornquist, M, Nebeling, L, Ehret, C, Barnett, M, McTiernan, A, Berger, NA, Goran, M, and Jeffery, R
- Subjects
Public Health ,Medical and Health Sciences ,Education - Published
- 2008
29. P-53 Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial
- Author
-
Pittock, S., primary, Barnett, M., additional, Bennett, J.L., additional, Berthele, A., additional, de Sèze, J., additional, Levy, M., additional, Nakashima, I., additional, Oreja-Guevara, C., additional, Palace, J., additional, Paul, F., additional, Pozzilli, C., additional, Allen, K., additional, Mashhoon, Y., additional, Yountz, M., additional, and Kim, H.J., additional
- Published
- 2023
- Full Text
- View/download PDF
30. Comparative effectiveness in multiple sclerosis: A methodological comparison
- Author
-
Roos, I, Diouf, I, Sharmin, S, Horakova, D, Havrdova, EK, Patti, F, Shaygannejad, V, Ozakbas, S, Izquierdo, G, Eichau, S, Onofrj, M, Lugaresi, A, Alroughani, R, Prat, A, Girard, M, Duquette, P, Terzi, M, Boz, C, Grand'Maison, F, Sola, P, Ferraro, D, Grammond, P, Turkoglu, R, Buzzard, K, Skibina, O, Yamou, B, Altintas, A, Gerlach, O, van Pesch, V, Blanco, Y, Maimone, D, Lechner-Scott, J, Bergamaschi, R, Karabudak, R, McGuigan, C, Cartechini, E, Barnett, M, Hughes, S, Sa, MJ, Solaro, C, Ramo-Tello, C, Hodgkinson, S, Spitaleri, D, Soysal, A, Petersen, T, Granella, F, de Gans, K, McCombe, P, Ampapa, R, Van Wijmeersch, B, van der Walt, A, Butzkueven, H, Prevost, J, Sanchez-Menoyo, JL, Laureys, G, Gouider, R, Castillo-Trivino, T, Gray, O, Aguera-Morales, E, Al-Asmi, A, Shaw, C, Deri, N, Al-Harbi, T, Fragoso, Y, Csepany, T, Sempere, AP, Trevino-Frenk, I, Schepel, J, Moore, F, Malpas, C, Kalincik, T, Roos, I, Diouf, I, Sharmin, S, Horakova, D, Havrdova, EK, Patti, F, Shaygannejad, V, Ozakbas, S, Izquierdo, G, Eichau, S, Onofrj, M, Lugaresi, A, Alroughani, R, Prat, A, Girard, M, Duquette, P, Terzi, M, Boz, C, Grand'Maison, F, Sola, P, Ferraro, D, Grammond, P, Turkoglu, R, Buzzard, K, Skibina, O, Yamou, B, Altintas, A, Gerlach, O, van Pesch, V, Blanco, Y, Maimone, D, Lechner-Scott, J, Bergamaschi, R, Karabudak, R, McGuigan, C, Cartechini, E, Barnett, M, Hughes, S, Sa, MJ, Solaro, C, Ramo-Tello, C, Hodgkinson, S, Spitaleri, D, Soysal, A, Petersen, T, Granella, F, de Gans, K, McCombe, P, Ampapa, R, Van Wijmeersch, B, van der Walt, A, Butzkueven, H, Prevost, J, Sanchez-Menoyo, JL, Laureys, G, Gouider, R, Castillo-Trivino, T, Gray, O, Aguera-Morales, E, Al-Asmi, A, Shaw, C, Deri, N, Al-Harbi, T, Fragoso, Y, Csepany, T, Sempere, AP, Trevino-Frenk, I, Schepel, J, Moore, F, Malpas, C, and Kalincik, T
- Abstract
BACKGROUND: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models. OBJECTIVE: To use the comparative effectiveness of fingolimod vs natalizumab to compare the results obtained with propensity score matching and marginal structural models. METHODS: Patients with clinically isolated syndrome or relapsing remitting MS who were treated with either fingolimod or natalizumab were identified in the MSBase registry. Patients were propensity score matched, and inverse probability of treatment weighted at six monthly intervals, using the following variables: age, sex, disability, MS duration, MS course, prior relapses, and prior therapies. Studied outcomes were cumulative hazard of relapse, disability accumulation, and disability improvement. RESULTS: 4608 patients (1659 natalizumab, 2949 fingolimod) fulfilled inclusion criteria, and were propensity score matched or repeatedly reweighed with marginal structural models. Natalizumab treatment was associated with a lower probability of relapse (PS matching: HR 0.67 [95% CI 0.62-0.80]; marginal structural model: 0.71 [0.62-0.80]), and higher probability of disability improvement (PS matching: 1.21 [1.02 -1.43]; marginal structural model 1.43 1.19 -1.72]). There was no evidence of a difference in the magnitude of effect between the two methods. CONCLUSIONS: The relative effectiveness of two therapies can be efficiently compared by either marginal structural models or propensity score matching when applied in clearly defined clinical contexts and in sufficiently powered cohorts.
- Published
- 2023
31. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
- Author
-
Daruwalla, C, Shaygannejad, V, Ozakbas, S, Havrdova, EK, Horakova, D, Alroughani, R, Boz, C, Patti, F, Onofrj, M, Lugaresi, A, Eichau, S, Girard, M, Prat, A, Duquette, P, Yamout, B, Khoury, SJ, Sajedi, SA, Turkoglu, R, Altintas, A, Skibina, O, Buzzard, K, Grammond, P, Karabudak, R, van der Walt, A, Butzkueven, H, Maimone, D, Lechner-Scott, J, Soysal, A, John, N, Prevost, J, Spitaleri, D, Ramo-Tello, C, Gerlach, O, Iuliano, G, Foschi, M, Ampapa, R, van Pesch, V, Barnett, M, Shalaby, N, D'hooghe, M, Kuhle, J, Sa, MJ, Fabis-Pedrini, M, Kermode, A, Mrabet, S, Gouider, R, Hodgkinson, S, Laureys, G, Van Hijfte, L, Macdonell, R, Oreja-Guevara, C, Cristiano, E, McCombe, P, Sanchez-Menoyo, JL, Singhal, B, Blanco, Y, Hughes, S, Garber, J, Solaro, C, McGuigan, C, Taylor, B, de Gans, K, Habek, M, Al-Asmi, A, Mihaela, S, Castillo Trivino, T, Al-Harbi, T, Rojas, JI, Gray, O, Khurana, D, Van Wijmeersch, B, Grigoriadis, N, Inshasi, J, Oh, J, Aguera-Morales, E, Fragoso, Y, Moore, F, Shaw, C, Baghbanian, SM, Shuey, N, Willekens, B, Hardy, TA, Decoo, D, Sempere, AP, Field, D, Wynford-Thomas, R, Cunniffe, NG, Roos, I, Malpas, CB, Coles, AJ, Kalincik, T, Brown, JWL, MSBase, SG, Daruwalla, C, Shaygannejad, V, Ozakbas, S, Havrdova, EK, Horakova, D, Alroughani, R, Boz, C, Patti, F, Onofrj, M, Lugaresi, A, Eichau, S, Girard, M, Prat, A, Duquette, P, Yamout, B, Khoury, SJ, Sajedi, SA, Turkoglu, R, Altintas, A, Skibina, O, Buzzard, K, Grammond, P, Karabudak, R, van der Walt, A, Butzkueven, H, Maimone, D, Lechner-Scott, J, Soysal, A, John, N, Prevost, J, Spitaleri, D, Ramo-Tello, C, Gerlach, O, Iuliano, G, Foschi, M, Ampapa, R, van Pesch, V, Barnett, M, Shalaby, N, D'hooghe, M, Kuhle, J, Sa, MJ, Fabis-Pedrini, M, Kermode, A, Mrabet, S, Gouider, R, Hodgkinson, S, Laureys, G, Van Hijfte, L, Macdonell, R, Oreja-Guevara, C, Cristiano, E, McCombe, P, Sanchez-Menoyo, JL, Singhal, B, Blanco, Y, Hughes, S, Garber, J, Solaro, C, McGuigan, C, Taylor, B, de Gans, K, Habek, M, Al-Asmi, A, Mihaela, S, Castillo Trivino, T, Al-Harbi, T, Rojas, JI, Gray, O, Khurana, D, Van Wijmeersch, B, Grigoriadis, N, Inshasi, J, Oh, J, Aguera-Morales, E, Fragoso, Y, Moore, F, Shaw, C, Baghbanian, SM, Shuey, N, Willekens, B, Hardy, TA, Decoo, D, Sempere, AP, Field, D, Wynford-Thomas, R, Cunniffe, NG, Roos, I, Malpas, CB, Coles, AJ, Kalincik, T, Brown, JWL, and MSBase, SG
- Abstract
BACKGROUND: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. OBJECTIVE: To determine whether early non-disabling relapses predict disability accumulation in RRMS. METHODS: We redefined mild relapses in MSBase as 'non-disabling', and moderate or severe relapses as 'disabling'. We used mixed-effects Cox models to compare 90-day confirmed disability accumulation events in people with exclusively non-disabling relapses within 2 years of RRMS diagnosis to those with no early relapses; and any early disabling relapses. Analyses were stratified by disease-modifying therapy (DMT) efficacy during follow-up. RESULTS: People who experienced non-disabling relapses within 2 years of RRMS diagnosis accumulated more disability than those with no early relapses if they were untreated (n = 285 vs 4717; hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.00-1.68) or given platform DMTs (n = 1074 vs 7262; HR = 1.33, 95% CI = 1.15-1.54), but not if given high-efficacy DMTs (n = 572 vs 3534; HR = 0.90, 95% CI = 0.71-1.13) during follow-up. Differences in disability accumulation between those with early non-disabling relapses and those with early disabling relapses were not confirmed statistically. CONCLUSION: This study suggests that early non-disabling relapses are associated with a higher risk of disability accumulation than no early relapses in RRMS. This risk may be mitigated by high-efficacy DMTs. Therefore, non-disabling relapses should be considered when making treatment decisions.
- Published
- 2023
32. AmelHap: Leveraging drone whole-genome sequence data to create a honey bee HapMap
- Author
-
Genética, antropología física y fisiología animal, Genetika,antropologia fisikoa eta animalien fisiologia, Parejo Feuz, Melanie, Talenti, A., Richardson, M., Vignal, A., Barnett, M., Wragg, D., Genética, antropología física y fisiología animal, Genetika,antropologia fisikoa eta animalien fisiologia, Parejo Feuz, Melanie, Talenti, A., Richardson, M., Vignal, A., Barnett, M., and Wragg, D.
- Abstract
Honey bee, Apis mellifera, drones are typically haploid, developing from an unfertilized egg, inheriting only their queen’s alleles and none from the many drones she mated with. Thus the ordered combination or ‘phase’ of alleles is known, making drones a valuable haplotype resource. We collated whole-genome sequence data for 1,407 drones, including 45 newly sequenced Scottish drones, collectively representing 19 countries, 8 subspecies and various hybrids. Following alignment to Amel_HAv3.1, variant calling and quality filtering, we retained 17.4 M high quality variants across 1,328 samples with a genotyping rate of 98.7%. We demonstrate the utility of this haplotype resource, AmelHap, for genotype imputation, returning >95% concordance when up to 61% of data is missing in haploids and up to 12% of data is missing in diploids. AmelHap will serve as a useful resource for the community for imputation from low-depth sequencing or SNP chip data, accurate phasing of diploids for association studies, and as a comprehensive reference panel for population genetic and evolutionary analyses.
- Published
- 2023
33. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
- Author
-
Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Daruwalla, C.; Shaygannejad, V.; Ozakbas, S.; Havrdova, EK.; Horakova, D.; Alroughani, R.; Boz, C.; Patti, F.; Onofrj, M.; Lugaresi, A.; Eichau, S.; Girard, M.; Prat, A.; Duquette, P.; Yamout, B.; Khoury, S.J.; Sajedi, S.A.; Turkoglu, R.; Skibina, O.; Buzzard, K.; Grammond, P.; Karabudak, R.; van der Walt, A.; Butzkueven, H.; Maimone, D.; Lechner-Scott, J.; Soysal, A.; John, N.; Prevost, J.; Spitaleri, D.; Ramo-Tello, C.; Gerlach, O.; Iuliano, G.; Foschi, M.; Ampapa, R.; van Pesch, V.; Barnett, M.; Shalaby, N.; D'hooghe, M.; Kuhle, J.; Sa, M.J.; Fabis-Pedrini, M.; Kermode, A.; Mrabet, S.; Gouider, R.; Hodgkinson, S.; Laureys, G.; Van Hijfte, L.; Macdonell, R.; Oreja-Guevara, C.; Cristiano, E.; McCombe, P.; Sanchez-Menoyo, J.L.; Singhal, B.; Blanco, Y.; Hughes, S.; Garber, J.; Solaro, C.; McGuigan, C.; Taylor, B.; de Gans, K.; Habek, M.; Al-Asmi, A.; Mihaela, S.; Castillo Triviño, T.; Al-Harbi, T.; Rojas, J.I.; Gray, O.; Khuran,a D.; Van Wijmeersch, B.; Grigoriadis, N.; Inshasi, J.; Oh, J.; Aguera-Morales, E.; Fragoso, Y.; Moore, F.; Shaw, C.; Baghbanian, S.M.; Shuey, N.; Willekens, B.; Hardy, T.A.; Decoo, D.; Sempere, A.P.; Field, D.; Wynford-Thomas, R.; Cunniffe, NG.; Roos, I.; Malpas, C.B.; Coles, A.J.; Kalincik, T.; Brown, J.W.L., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Daruwalla, C.; Shaygannejad, V.; Ozakbas, S.; Havrdova, EK.; Horakova, D.; Alroughani, R.; Boz, C.; Patti, F.; Onofrj, M.; Lugaresi, A.; Eichau, S.; Girard, M.; Prat, A.; Duquette, P.; Yamout, B.; Khoury, S.J.; Sajedi, S.A.; Turkoglu, R.; Skibina, O.; Buzzard, K.; Grammond, P.; Karabudak, R.; van der Walt, A.; Butzkueven, H.; Maimone, D.; Lechner-Scott, J.; Soysal, A.; John, N.; Prevost, J.; Spitaleri, D.; Ramo-Tello, C.; Gerlach, O.; Iuliano, G.; Foschi, M.; Ampapa, R.; van Pesch, V.; Barnett, M.; Shalaby, N.; D'hooghe, M.; Kuhle, J.; Sa, M.J.; Fabis-Pedrini, M.; Kermode, A.; Mrabet, S.; Gouider, R.; Hodgkinson, S.; Laureys, G.; Van Hijfte, L.; Macdonell, R.; Oreja-Guevara, C.; Cristiano, E.; McCombe, P.; Sanchez-Menoyo, J.L.; Singhal, B.; Blanco, Y.; Hughes, S.; Garber, J.; Solaro, C.; McGuigan, C.; Taylor, B.; de Gans, K.; Habek, M.; Al-Asmi, A.; Mihaela, S.; Castillo Triviño, T.; Al-Harbi, T.; Rojas, J.I.; Gray, O.; Khuran,a D.; Van Wijmeersch, B.; Grigoriadis, N.; Inshasi, J.; Oh, J.; Aguera-Morales, E.; Fragoso, Y.; Moore, F.; Shaw, C.; Baghbanian, S.M.; Shuey, N.; Willekens, B.; Hardy, T.A.; Decoo, D.; Sempere, A.P.; Field, D.; Wynford-Thomas, R.; Cunniffe, NG.; Roos, I.; Malpas, C.B.; Coles, A.J.; Kalincik, T.; Brown, J.W.L., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine
- Abstract
Background: the prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: to determine whether early non-disabling relapses predict disability accumulation in RRMS. Methods: we redefined mild relapses in MSBase as 'non-disabling', and moderate or severe relapses as 'disabling'. We used mixed-effects Cox models to compare 90-day confirmed disability accumulation events in people with exclusively non-disabling relapses within 2 years of RRMS diagnosis to those with no early relapses; and any early disabling relapses. Analyses were stratified by disease-modifying therapy (DMT) efficacy during follow-up. Results: people who experienced non-disabling relapses within 2 years of RRMS diagnosis accumulated more disability than those with no early relapses if they were untreated (n = 285 vs 4717; hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.00-1.68) or given platform DMTs (n = 1074 vs 7262; HR = 1.33, 95% CI = 1.15-1.54), but not if given high-efficacy DMTs (n = 572 vs 3534; HR = 0.90, 95% CI = 0.71-1.13) during follow-up. Differences in disability accumulation between those with early non-disabling relapses and those with early disabling relapses were not confirmed statistically. Conclusion: this study suggests that early non-disabling relapses are associated with a higher risk of disability accumulation than no early relapses in RRMS. This risk may be mitigated by high-efficacy DMTs. Therefore, non-disabling relapses should be considered when making treatment decisions., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by National Health and Medical Research Council of Australia (fellowship nos.1140766 and 1080518, project grant nos. 1129189 and 1083539), the University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship), National Institute for Health and Care Research (UK) Advanced Fellowship (grant no. 301728; recipient JWLB) and Academic Clinical Fellowship (grant no. EAN/ACA-006/7488627/C; recipient CD). The MSBase Foundation is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme, and Teva. Role of the Funder/Sponsor: The National Health and Medical Research Council of Australia, the University of Melbourne and the National Institute for Health and Care Research (UK) had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
- Published
- 2023
34. Five scenarios of the Israel-Palestinian relationship in 2002: Works in progress
- Author
-
Stein, JG, Barnett, M, Frankel, B, Gause, G, Gerner, DJ, Herrmann, R, Jentleson, BW, Kaye, DD, Lebow, RN, Lynch, M, Solingen, E, Spiro, DE, Sylvan, DA, and Weber, S
- Subjects
Political Science ,History and Philosophy of Specific Fields ,Strategic ,Defence & Security Studies - Published
- 1998
35. Registration of LCS ‘Valiant’ hard red winter wheat
- Author
-
Baenziger, P. S., primary, Masterson, S. D., additional, Boehm, J. D., additional, Belamkar, V., additional, Barnett, M. D., additional, Rose, D. J., additional, Xu, L., additional, Wegulo, S. N., additional, Regassa, T., additional, Easterly, A. C., additional, Creech, C. F., additional, Santra, D. K., additional, Kruger, G. R., additional, Hergert, G. W., additional, Klein, R. N., additional, Jin, Y., additional, Kolmer, J., additional, Chen, M.‐S., additional, Hein, G. L., additional, Bowden, R. L., additional, Guttieri, M. J., additional, Bai, G., additional, Salah, I. El‐Basyoni, additional, and Poland, J., additional
- Published
- 2022
- Full Text
- View/download PDF
36. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study
- Author
-
Terzi, M., Rojas, J. I., Barnett, M., Fragoso, Y., Cartechini, E., Pucci, E., Willekens, B., Butler, E., Blanco, Y., Grigoriadis, N., Van Hijfte, L., Dirks, P., Liu, C., Rouzic, E. Muros-Le, Butzkueven, H., Al-Harbi, T., Laureys, G., Ozakbas, S., Spelman, T., Alroughani, R., Menoyo, J. L. Sanchez, Van Pesch, V., Kalincik, T., Lechner-Scott, J., Van der Walt, A., Grand'Maison, F., Boz, C., Buzzard, K., and Skibina, O.
- Published
- 2022
37. Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset
- Author
-
Rojas, J. I., Barnett, M., Jakimovski, D., Butzkueven, H., Weinstock-Guttman, B., Yang, S., Boz, C., Altintas, A., Dwyer, M. G., Ozakbas, S., van Pesch, V., Gaillard, F., Desmond, P., Kalincik, T., Bergsland, N., Wang, C., Kyle, K., and Zivadinov, R.
- Published
- 2022
38. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS
- Author
-
Atkins, H., Burman, J., Massey, J., Sutton, I., Withers, B., Macdonell, R., Grigg, A., Torkildsen, O., Bo, L., Lehmann, A., Horakova, D., Havrdova, E., Krasulova, E., Trneny, M., Kozak, T., van der Walt, A., Butzkueven, H., McCombe, P., Van Wijmeersch, B., Buzzard, K., Skibina, O., Lechner-Scott, J., Willekens, B., Barnett, M., Cartechini, E., Ozakbas, S., Alroughani, R., Izquierdo, G., Boz, C., Kalincik, T., Sharman, S., Roos, I., Freedman, M., Eichau, S., Snowden, J., Sharrack, B., Turkoglu, R., Prevost, J., Slee, M., Soysal, A., Khoury, S., Lugaresi, A., Onofrj, M., Grammond, P., Duquette, P., Girard, M., Prat, A., Terzi, M., Patti, F., and Kuhle, J.
- Published
- 2022
39. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
- Author
-
Butler, E., Van Pesch, V., Shalaby, N., Kermode, A., Maimone, D., Blanco, Y., Altintas, A., Turkoglu, R., Butzkueven, H., Van der Walt, A., Skibina, O., Buzzard, K., Lechner-Scott, J., Grammond, P., Khoury, S. J., Yamout, B., Grand'Maison, F., Karabudak, R., Amato, M. P., Terzi, M., Duquette, P., Girard, M., Prat, A., Weinstock-Guttman, B., Lugaresi, A., Onofrj, M., Zakaria, M., Boz, C., Eichau, S., Izquierdo, G., Shaygannejad, V., Alroughani, R., Patti, F., Havrdova, E. K., Horakova, D., Ozakbas, S., Sanchez, M. Martinez, Malpas, C., Simpson-Yap, S., Roos, I., Sharmin, S., Sidhom, Y., Gouider, R., Gerlach, O., Soysal, A., Barnett, M., Kuhle, J., Hughes, S., Sa, M. Jose, and Kalincik, T.
- Published
- 2022
40. Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation
- Author
-
Macdonell, R., Zhu, C., Kalincik, T., Horakova, D., Zhen, Z., Buzzard, K., Skibina, O., Alroughani, R., Izquierdo, G., Eichau, S., Kuhle, J., Patti, F., Grand'Maison, F., Hodgkinson, S., Grammond, P., Lechner-Scott, J., Butler, E., Prat, A., Girard, M., Butzkueven, H., Van der Walt, A., Merlo, D., Monif, M., Jokubaitis, V., Khoury, S. J., Yamout, B., Garber, J., Kermode, A., Van Hijfte, L., Laureys, G., Boz, C., Terzi, M., Prevost, J., Gerlach, O., Van Wijmeersch, B., Barnett, M., Van Pesch, V., Sa, M. Jose, Slee, M., Ozakbas, S., Weinstock-Guttman, B., and Duquette, P.
- Published
- 2022
41. Supplement to: Opioid-prescribing patterns of emergency physicians and risk of long-term use.
- Author
-
Barnett, M L, Olenski, A R, and Jena, A B
- Published
- 2017
42. Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations
- Author
-
Klistorner, A., Graham, E. C., Yiannikas, C., Barnett, M., Parratt, J., Garrick, R., Wang, C., You, Y., and Graham, S. L.
- Published
- 2017
- Full Text
- View/download PDF
43. The Palgrave Handbook of Critical Thinking in Higher Education
- Author
-
M. Davies, R. Barnett, M. Davies, R. Barnett and M. Davies, R. Barnett, M. Davies, R. Barnett
- Published
- 2015
44. Evaluating potential artefacts of photo-reversal on behavioural studies with nocturnal invasive sea lamprey (Petromyzon marinus)
- Author
-
Barnett, M., Imre, I., Wagner, C.M., Rocco, R.T. Di, Johnson, N.S., and Brown, G.E.
- Subjects
Sea lamprey -- Environmental aspects -- Behavior ,Invasive species -- Environmental aspects -- Behavior ,Zoology and wildlife conservation - Abstract
Abstract: Sea lampreys (Petromyzon marinus L., 1758) are nocturnal, so experiments evaluating their behaviour to chemosensory cues have typically been conducted at night. However, given the brief timeframe each year [...]
- Published
- 2016
45. Psyma of Sinorhizobium Meliloti: Nitrogen Fixation and More
- Author
-
Barnett, M. J., Kahn, M. L., Palacios, Rafael, editor, and Newton, William E., editor
- Published
- 2005
- Full Text
- View/download PDF
46. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
- Author
-
Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E.K., Patti F., Ozakbas S., Izquierdo G., Eichau S., Shaygannejad V., Onofrj M., Lugaresi A., Alroughani R., Prat A., Larochelle C., Girard M., Duquette P., Terzi M., Boz C., Grand'Maison F., Sola P., Ferraro D., Grammond P., Butzkueven H., Buzzard K., Skibina O., Yamout B.I., Karabudak R., Gerlach O., Lechner-Scott J., Maimone D., Bergamaschi R., Van Pesch V., Iuliano G., Cartechini E., JosA Sa M., Ampapa R., Barnett M., Hughes S.E., Ramo-Tello C.M., Hodgkinson S., Spitaleri D.L.A., Petersen T., Butler E.G., Slee M., McGuigan C., McCombe P.A., Granella F., Cristiano E., Prevost J., Taylor B.V., Sa Nchez-Menoyo J.L., Laureys G., Van Hijfte L., Vucic S., Macdonell R.A., Gray O., Olascoaga J., Deri N., Fragoso Y.D., Shaw C., Kalincik T., Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E.K., Patti F., Ozakbas S., Izquierdo G., Eichau S., Shaygannejad V., Onofrj M., Lugaresi A., Alroughani R., Prat A., Larochelle C., Girard M., Duquette P., Terzi M., Boz C., Grand'Maison F., Sola P., Ferraro D., Grammond P., Butzkueven H., Buzzard K., Skibina O., Yamout B.I., Karabudak R., Gerlach O., Lechner-Scott J., Maimone D., Bergamaschi R., Van Pesch V., Iuliano G., Cartechini E., JosA Sa M., Ampapa R., Barnett M., Hughes S.E., Ramo-Tello C.M., Hodgkinson S., Spitaleri D.L.A., Petersen T., Butler E.G., Slee M., McGuigan C., McCombe P.A., Granella F., Cristiano E., Prevost J., Taylor B.V., Sa Nchez-Menoyo J.L., Laureys G., Van Hijfte L., Vucic S., Macdonell R.A., Gray O., Olascoaga J., Deri N., Fragoso Y.D., Shaw C., and Kalincik T.
- Abstract
BACKGROUND AND OBJECTIVES: The severity of multiple sclerosis (MS) varies widely among individuals. Understanding the determinants of this heterogeneity will help clinicians optimize the management of MS. The aim of this study was to investigate the association between latitude of residence, ultraviolet B radiation exposure (UVB) and the severity of MS. METHOD(S): This observational study used the MSBase registry data. The included patients met the 2005 or 2010 McDonald diagnostic criteria for MS and had a minimum dataset recorded in the registry (date of birth, sex, clinic location, date of MS symptom onset, disease phenotype at baseline and censoring, and >=1 EDSS [Expanded Disability Status Scale] score recorded). The latitude of each study center and cumulative annualized UVB dose at study center (calculated from NASA's Total Ozone Mapping Spectrometer) at ages 6 and 18 and the year of disability assessment were calculated. Disease severity was quantified with MS Severity Score (MSSS). Quadratic regression was used to model the associations between latitude, UVB and MSSS. RESULT(S): 46,128 patients contributing 453,208 visits and a cumulative follow-up of 351,196 patient-years (70% women, mean age 39.2+/-12, resident between latitudes 19degree35' and 56degree16') were included in this study. Latitude showed a non-linear association with MS severity. In latitudes greater than 40degree, more severe disease was associated with higher latitudes (beta=0.08, 95%CI: 0.04 to 0.12). For example, this translates into a mean difference of 1.3 points of MSSS between patients living in Madrid and Copenhagen. No such association was observed in latitudes <40degree (beta=-0.02, 95% CI:-0.06 to 0.03). The overall disability accrual was faster in those with a lower level of estimated UVB exposure before the age of 6 (beta=- 0.5, 95% CI: -0.6 to 0.4) and 18 years (beta=- 0.6, 95%CI:-0.7 to 0.4), as well as with lower life-time UVB exposure at the time of disability assessment (be
- Published
- 2022
47. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
- Author
-
Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., Duquette P., Onofrj M., Lugaresi A., Grand'Maison F., Grammond P., Sola P., Ferraro D., Terzi M., Gerlach O., Alroughani R., Boz C., Shaygannejad V., van Pesch V., Cartechini E., Kappos L., Lechner-Scott J., Bergamaschi R., Turkoglu R., Solaro C., Iuliano G., Granella F., Van Wijmeersch B., Spitaleri D., Slee M., McCombe P., Prevost J., Ampapa R., Ozakbas S., Sanchez-Menoyo J., Soysal A., Vucic S., Petersen T., de Gans K., Butler E., Hodgkinson S., Sidhom Y., Gouider R., Cristiano E., Castillo-Trivino T., Saladino M., Barnett M., Moore F., Rozsa C., Yamout B., Skibina O., van der Walt A., Buzzard K., Gray O., Hughes S., Sempere A.P., Singhal B., Fragoso Y., Shaw C., Kermode A., Taylor B., Simo M., Shuey N., Al-Harbi T., Macdonell R., Dominguez J.A., Csepany T., Sirbu C., Sormani M.P., Butzkueven H., Kalincik T., Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., Duquette P., Onofrj M., Lugaresi A., Grand'Maison F., Grammond P., Sola P., Ferraro D., Terzi M., Gerlach O., Alroughani R., Boz C., Shaygannejad V., van Pesch V., Cartechini E., Kappos L., Lechner-Scott J., Bergamaschi R., Turkoglu R., Solaro C., Iuliano G., Granella F., Van Wijmeersch B., Spitaleri D., Slee M., McCombe P., Prevost J., Ampapa R., Ozakbas S., Sanchez-Menoyo J., Soysal A., Vucic S., Petersen T., de Gans K., Butler E., Hodgkinson S., Sidhom Y., Gouider R., Cristiano E., Castillo-Trivino T., Saladino M., Barnett M., Moore F., Rozsa C., Yamout B., Skibina O., van der Walt A., Buzzard K., Gray O., Hughes S., Sempere A.P., Singhal B., Fragoso Y., Shaw C., Kermode A., Taylor B., Simo M., Shuey N., Al-Harbi T., Macdonell R., Dominguez J.A., Csepany T., Sirbu C., Sormani M.P., Butzkueven H., and Kalincik T.
- Abstract
Background and purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. Method(s): In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. Result(s): The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score >1.5). Conclusion(s): Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.Copyright © 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behal
- Published
- 2022
48. Confirmed disability progression as a marker of permanent disability in multiple sclerosis
- Author
-
Sharmin, S., Bovis, F., Malpas, C., Horakova, D., Havrdova, E.K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Gerlach, O., Alroughani, R., Boz, C., Shaygannejad, V., van Pesch, V., Cartechini, E., Kappos, L., Lechner‐Scott, J., Bergamaschi, R., Turkoglu, R., Solaro, C., Iuliano, G., Granella, F., Van Wijmeersch, B., Spitaleri, D., Slee, M., McCombe, P., Prevost, J., Ampapa, R., Ozakbas, S., Sanchez‐Menoyo, J.L., Soysal, A., Vucic, S., Petersen, T., de Gans, K., Butler, E., Hodgkinson, S., Sidhom, Y., Gouider, R., Cristiano, E., Castillo‐Triviño, T., Saladino, M.L., Barnett, M., Moore, F., Rozsa, C., Yamout, B., Skibina, O., van der Walt, A., Buzzard, K., Gray, O., Hughes, S., Sempere, A.P., Singhal, B., Fragoso, Y., Shaw, C., Kermode, A., Taylor, B., Simo, M., Shuey, N., Al‐Harbi, T., Macdonell, R., Dominguez, J.A., Csepany, T., Sirbu, C.A., Sormani, M.P., Butzkueven, H., Kalincik, T., Sharmin, S., Bovis, F., Malpas, C., Horakova, D., Havrdova, E.K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Gerlach, O., Alroughani, R., Boz, C., Shaygannejad, V., van Pesch, V., Cartechini, E., Kappos, L., Lechner‐Scott, J., Bergamaschi, R., Turkoglu, R., Solaro, C., Iuliano, G., Granella, F., Van Wijmeersch, B., Spitaleri, D., Slee, M., McCombe, P., Prevost, J., Ampapa, R., Ozakbas, S., Sanchez‐Menoyo, J.L., Soysal, A., Vucic, S., Petersen, T., de Gans, K., Butler, E., Hodgkinson, S., Sidhom, Y., Gouider, R., Cristiano, E., Castillo‐Triviño, T., Saladino, M.L., Barnett, M., Moore, F., Rozsa, C., Yamout, B., Skibina, O., van der Walt, A., Buzzard, K., Gray, O., Hughes, S., Sempere, A.P., Singhal, B., Fragoso, Y., Shaw, C., Kermode, A., Taylor, B., Simo, M., Shuey, N., Al‐Harbi, T., Macdonell, R., Dominguez, J.A., Csepany, T., Sirbu, C.A., Sormani, M.P., Butzkueven, H., and Kalincik, T.
- Abstract
Background and purpose The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. Methods In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. Results The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29–0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score ˃1.5). Conclusions Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.
- Published
- 2022
49. Confirmed disability progression as a marker of permanent disability in multiple sclerosis
- Author
-
Sharmin, S, Malpas, C, Lechner-Scott, J, Slee, M, McCombe, P, Vucic, S, Butler, E, Hodgkinson, S, Barnett, M, Skibina, O, van der Walt, A, Buzzard, K, Shaw, C, Kermode, A, Taylor, B, Shuey, N, Macdonell, R, Butzkueven, H, Kalincik, T, Sharmin, S, Malpas, C, Lechner-Scott, J, Slee, M, McCombe, P, Vucic, S, Butler, E, Hodgkinson, S, Barnett, M, Skibina, O, van der Walt, A, Buzzard, K, Shaw, C, Kermode, A, Taylor, B, Shuey, N, Macdonell, R, Butzkueven, H, and Kalincik, T
- Abstract
BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. METHODS: In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. RESULTS: The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score ˃1.5). CONCLUSIONS: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.
- Published
- 2022
50. Older adults have delayed amino acid absorption after a high protein mixed breakfast meal
- Author
-
Milan, A. M., D’Souza, R. F., Pundir, S., Pileggi, C. A., Barnett, M. P. G., Markworth, J. F., Cameron-Smith, D., and Mitchell, Cameron
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.